"Ozempic face" is the colloquial term for facial volume loss after rapid weight loss on GLP-1 therapy. It's real, it's predictable, and — with the right preparation — it's largely preventable. This is the practical guide.
Why it happens
Subcutaneous fat in the face, especially the buccal (cheek) and submandibular (under the jaw) areas, is highly responsive to overall body fat loss. Rapid drops in body fat draw down those depots quickly. The skin and underlying soft tissue have less time to remodel than they would in slower weight loss. The result is a hollower, more skeletal appearance — most visible in patients who were lower BMI to start.
Who is most affected
- Patients with BMI 27–32 who lose more than 15% body weight
- Patients over 45 (skin elasticity declines)
- Patients losing more than 1.5% body weight per week sustained
- Patients with low protein intake and no resistance training (combined sarcopenic loss)
What actually helps prevent it
- Slow titration — stretch out the time to maximum dose; aim for ~0.75% body weight per week, not 1.5%
- Protein floor — 1.6 g/kg body weight as the daily minimum
- Resistance training — facial appearance correlates with overall body composition; preserving lean mass helps the face stay full
- Hydration — chronic dehydration accentuates facial volume loss
- Sleep — short sleep accelerates skin aging and impairs lean-mass retention
Cosmetic interventions, if needed
For patients who experience significant facial volume loss despite the above, dermal fillers (hyaluronic acid, polylactic acid, calcium hydroxylapatite) and biostimulators are the standard interventions. These should be performed by a board-certified dermatologist or facial plastic surgeon. We don't recommend pursuing cosmetic intervention until weight has stabilized — typically 6 months after reaching goal.
Bottom line
Ozempic face is the predictable result of rapid weight loss in patients who were not at very high BMI to start, especially without protein and resistance-training support. The mitigation protocol is the same as the muscle-preservation protocol. The combined intervention is one of the highest-leverage things you can do on GLP-1 therapy.
NexLife is our editorial pick (94/100 on the v4.1 methodology). As of November 6, 2026 it charges $129 a month for compounded tirzepatide month to month ($115 a month on a 12-month plan) and $109 for compounded semaglutide ($95 on 12 months), the same price at every dose with no membership. Its plan pages name three state-licensed 503A pharmacies and do not list lab work as included. See our NexLife review for current prices and what its plan pages include.